Marker Therapeutics Appoints Kathryn Penkus Corzo To Board To Strengthen Cell Therapy Leadership

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based therapies for blood cancers and solid tumors, announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to its Board of Directors, effective November 1, 2025. Ms. Penkus Corzo brings over three decades of leadership experience across R&D, clinical development, regulatory strategy, and commercialization, strengthening Marker’s governance and strategic oversight as it advances its novel cell therapy platform.

“We are pleased to welcome Kathryn to our Board of Directors,” said Juan Vera, M.D., President and CEO of Marker Therapeutics. “We believe in the strong clinical benefit we have observed with our lead asset MT-601 and remain committed to advancing the APOLLO program towards a future pivotal study in patients with CAR-relapsed Diffuse Large B Cell Lymphoma (DLBCL). As we are advancing into the next stage of clinical development, we have decided to strategically strengthen our Board of Directors to support this critical next phase. Kathryn’s strong background in oncology and extensive experience in global product commercialization will be invaluable as we continue to advance our clinical and corporate objectives.”

Ms. Penkus Corzo most recently served as President and Chief Operating Officer at bit.bio Ltd, a company pioneering induced pluripotent stem cell (iPSC) technology for human health. There, she led expansion efforts across commercial and therapeutic portfolios, built scalable operations, and drove growth in both value creation and revenue. Her earlier career includes senior roles at Takeda Ventures, where she led oncology cell therapy development, and major biopharma companies such as Sanofi Genzyme, Hoffmann-La Roche, Eli Lilly, and Syndax Pharmaceuticals, where she helped bring several blockbuster oncology drugs to market.

“I am honored to join Marker’s Board of Directors at such a pivotal time for the Company,” said Ms. Penkus Corzo. “Marker’s Multi-Antigen Recognizing (MAR) T cell platform represents a next-generation approach in cell therapy—addressing key limitations of current treatments with the potential to offer improved clinical outcomes to patients with limited therapeutic options. I am inspired by the team’s scientific rigor and commitment to patients, and I look forward to contributing to the advancement of Marker’s clinical programs and long-term growth.”

Marker’s proprietary multi-antigen recognizing (MAR) T cell platform, previously called multiTAA-specific T cells, represents a unique, non-genetically modified cell therapy approach. By expanding tumor-specific T cells from a patient’s or donor’s blood, MAR-T cells can recognize a broad spectrum of tumor antigens, reducing the risk of tumor escape. Unlike genetically engineered T cell therapies, MAR-T cells are expected to be simpler and more cost-effective to manufacture while maintaining strong safety and efficacy potential. Marker believes this approach could redefine the therapeutic landscape in cell-based cancer treatments.